These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 21831734)

  • 41. Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: Are they really heterogeneous? Insights from the FFCD-GTE national cohort.
    Walter T; Tougeron D; Baudin E; Le Malicot K; Lecomte T; Malka D; Hentic O; Manfredi S; Bonnet I; Guimbaud R; Coriat R; Lepère C; Desauw C; Thirot-Bidault A; Dahan L; Roquin G; Aparicio T; Legoux JL; Lombard-Bohas C; Scoazec JY; Lepage C; Cadiot G;
    Eur J Cancer; 2017 Jul; 79():158-165. PubMed ID: 28501762
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy and Toxicity of 5-Fluorouracil-Oxaliplatin in Gastroenteropancreatic Neuroendocrine Neoplasms.
    Merola E; Dal Buono A; Denecke T; Arsenic R; Pape UF; Jann H; Wiedenmann B; Pavel ME
    Pancreas; 2020 Aug; 49(7):912-917. PubMed ID: 32658073
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Primary treatment of regional and disseminated pancreatic cancer with hexamethylmelamine, mitomycin C and 5-fluorouracil infusion.
    Bruckner HW; Kalman J; Spigelman M; Gorbaty MI; Butwell N; Storch J; McKenna A
    Oncology; 1989; 46(6):366-71. PubMed ID: 2511535
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours.
    Bajetta E; Ferrari L; Procopio G; Catena L; Ferrario E; Martinetti A; Di Bartolomeo M; Buzzoni R; Celio L; Vitali M; Beretta E; Seregni E; Bombardieri E
    Ann Oncol; 2002 Apr; 13(4):614-21. PubMed ID: 12056713
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Low dose DTIC is effective and safe in pretreated patients with well differentiated neuroendocrine tumors.
    Mueller D; Krug S; Majumder M; Rinke A; Gress TM
    BMC Cancer; 2016 Aug; 16():645. PubMed ID: 27538897
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluating lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours.
    Lepage C; Dahan L; Bouarioua N; Toumpanakis C; Legoux JL; Le Malicot K; Guimbaud R; Smith D; Tougeron D; Lievre A; Cadiot G; Di Fiore F; Bouhier-Leporrier K; Hentic O; Faroux R; Pavel M; Borbath I; Valle JW; Rinke A; Scoazec JY; Ducreux M; Walter T
    Dig Liver Dis; 2017 May; 49(5):568-571. PubMed ID: 28292641
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of Endostar combined with chemotherapy in advanced well-differentiated pancreatic neuroendocrine tumors.
    Cheng YJ; Meng CT; Ying HY; Zhou JF; Yan XY; Gao X; Zhou N; Bai CM
    Medicine (Baltimore); 2018 Nov; 97(45):e12750. PubMed ID: 30407280
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Treatment Response and Outcomes of Grade 3 Pancreatic Neuroendocrine Neoplasms Based on Morphology: Well Differentiated Versus Poorly Differentiated.
    Raj N; Valentino E; Capanu M; Tang LH; Basturk O; Untch BR; Allen PJ; Klimstra DS; Reidy-Lagunes D
    Pancreas; 2017 Mar; 46(3):296-301. PubMed ID: 27759713
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Chemotherapy for neuroendocrine tumors: the Beatson Oncology Centre experience.
    Hatton MQ; Reed NS
    Clin Oncol (R Coll Radiol); 1997; 9(6):385-9. PubMed ID: 9448967
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Appendix 6: Cancer of the pancreas: MCBS eUpdate published online 20 June 2017 (www.esmo.org/Guidelines/Gastrointestinal-Cancers).
    ESMO Guidelines Committee
    Ann Oncol; 2017 Jul; 28(suppl_4):iv157. PubMed ID: 28881927
    [No Abstract]   [Full Text] [Related]  

  • 51. Appropriateness of systemic treatments in unresectable metastatic well-differentiated pancreatic neuroendocrine tumors.
    Strosberg JR; Fisher GA; Benson AB; Anthony LB; Arslan B; Gibbs JF; Greeno E; Iyer RV; Kim MK; Maples WJ; Philip PA; Wolin EM; Cherepanov D; Broder MS
    World J Gastroenterol; 2015 Feb; 21(8):2450-9. PubMed ID: 25741154
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [An autopsied case of metastatic endocrine carcinoma of the pancreas with primary site difficult to identify].
    Nishimori H; Takahashi S; Nagasaki E; Kobayashi T; Yokoyama M; Shinozaki E; Mishima Y; Terui Y; Chin K; Mizunuma N; Ito Y; Inamura K; Hatake K
    Gan To Kagaku Ryoho; 2005 May; 32(5):671-3. PubMed ID: 15918570
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Metastatic pancreatic neuroendocrine tumors and chemotherapy: evidences and perspectives].
    Gómez Raposo C; Gómez Senent S; González Barón M
    Med Clin (Barc); 2007 Mar; 128(9):357; author reply 357-8. PubMed ID: 17376367
    [No Abstract]   [Full Text] [Related]  

  • 54. A phase II trial of dacarbazine, fluorouracil and epirubicin in patients with neuroendocrine tumours. A study by the Italian Trials in Medical Oncology (I.T.M.O.) Group.
    Di Bartolomeo M; Bajetta E; Bochicchio AM; Carnaghi C; Somma L; Mazzaferro V; Visini M; Gebbia V; Tumolo S; Ballatore P
    Ann Oncol; 1995 Jan; 6(1):77-9. PubMed ID: 7710986
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Everolimus in Pancreatic Neuroendocrine Carcinomas G3.
    Panzuto F; Rinzivillo M; Spada F; Antonuzzo L; Ibrahim T; Campana D; Fazio N; Delle Fave G
    Pancreas; 2017 Mar; 46(3):302-305. PubMed ID: 28099254
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Management of metabolic disorders induced by everolimus in patients with differentiated neuroendocrine tumors: expert proposals].
    Lombard-Bohas C; Cariou B; Vergès B; Coriat R; N'guyen T; François E; Hammel P; Niccoli P; Hentic O
    Bull Cancer; 2014 Feb; 101(2):175-83. PubMed ID: 24557872
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Irinotecan-based chemotherapy in extrapulmonary neuroendocrine carcinomas: survival and safety data from a multicentric Italian experience.
    Bardasi C; Spallanzani A; Benatti S; Spada F; Laffi A; Antonuzzo L; Lavacchi D; Marconcini R; Ferrari M; Rimini M; Caputo F; Santini C; Cerma K; Casadei-Gardini A; Andrikou K; Salati M; Bertolini F; Fontana A; Dominici M; Luppi G; Gelsomino F
    Endocrine; 2021 Dec; 74(3):707-713. PubMed ID: 34231124
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Streptozocin chemotherapy for advanced/metastatic well-differentiated neuroendocrine tumors: an analysis of a multi-center survey in Japan.
    Aoki T; Kokudo N; Komoto I; Takaori K; Kimura W; Sano K; Takamoto T; Hashimoto T; Okusaka T; Morizane C; Ito T; Imamura M
    J Gastroenterol; 2015 Jul; 50(7):769-75. PubMed ID: 25348496
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma.
    Panzuto F; Di Fonzo M; Iannicelli E; Sciuto R; Maini CL; Capurso G; Milione M; Cattaruzza MS; Falconi M; David V; Ziparo V; Pederzoli P; Bordi C; Delle Fave G
    Ann Oncol; 2006 Mar; 17(3):461-6. PubMed ID: 16364959
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Treatment of poorly differentiated neuroendocrine carcinoma of the pancreas.
    Gupta A; Duque M; Saif MW
    JOP; 2013 Jul; 14(4):381-3. PubMed ID: 23846932
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.